Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.

Arrowhead Pharmaceuticals, Inc.

Chardan Capital analyst Keay Nakae maintained a Buy rating on Arrowhead Pharmaceuticals yesterday and set a price target of $115.00. According to T...

Arrowhead Pharmaceuticals (ARWR) Gets a Buy from Chardan Capital

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PTC Therapeutics (PTCT) and Arrowhead Pharmaceutical...

Analysts’ Top Healthcare Picks: PTC Therapeutics (PTCT), Arrowhead Pharmaceuticals (ARWR)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Claritev (CTEV), Ionis Pharmaceuticals (IONS) and Ar...

Analysts Offer Insights on Healthcare Companies: Claritev (CTEV), Ionis Pharmaceuticals (IONS) and Arrowhead Pharmaceuticals (ARWR)

Arrowhead Pharmaceuticals stock saw major gains after the company announced new results from a Phase 3 trial.


Arrowhead Pharmaceuticals (ARWR) Stock Soars on Strong Phase 3 Trial Results

Arrowhead Pharmaceuticals, Inc. ($ARWR) announced an update on their ongoing clinical study. Arrowhead’s new first-in-human study of ARO-033 aims t...

Arrowhead’s ARO-033 First-in-Human Trial: What Early Safety Progress Means for ARWR Investors

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arrowhead Pharmaceuticals (ARWR), Otsuka Holdings Co...

Analysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Otsuka Holdings Co (OTSKY)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arrowhead Pharmaceuticals (ARWR) and BrightSpring He...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ARWR	$87.65	+2.12%	948.27K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ARWR	$87.65	+2.1%	948.27K
3
4
5
6

ARWR

ARWR

Get Arrowhead Pharmaceuticals, Inc. Data in Excel

Get Arrowhead Pharmaceuticals, Inc. Data in Excel